OnCusp Therapeutics is transforming a growing portfolio of cutting-edge molecules into innovative treatments that deliver help and hope to cancer patients worldwide.
OnCusp’s unique combination of translational expertise and global industry network make us the optimal partner to transform cutting-edge research assets into clinically proven therapeutics.
For Chinese biotechs, the out-licensing business is scorching hot. Could geopolitics rain on their parade?
OnCusp Therapeutics Announces First Patient Dosed in Phase 1 Trial of CUSP06 in Patients with Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumors
